Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.

Eli Lilly & Company has increased the price of Mounjaro in the UK by 170% to make it cheaper in the US, while Google has issued a cybersecurity warning to its 1.8 billion Gmail users, and the FDA has ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Investors bought in after the company got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Former Uber regional manager and Oscar Health COO has set out on her own to help busy people get help with their schedules by ...

COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug ...

The Global Women’s Health Market is expected to witness a growth rate of 4-5% in the next five years. Growing incidence of ...

FutureWise Research today announces the upcoming release of its comprehensive report, Alzheimer’s Disease Diagnostic Market – ...

Boston: Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to ...

Eli Lilly and Company witnessed a notable insider buy recently. David Ricks, the Chairman, invested a hefty $1.1 million in ...